Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted ...
VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that …